• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?靶向卵巢癌中的叶酸受体是否已成熟？
Oncologist. 2019 Apr;24(4):425-429. doi: 10.1634/theoncologist.2018-0459. Epub 2019 Jan 11.
2
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.用于治疗上皮性卵巢癌的处于临床前和早期临床开发阶段的叶酸受体α拮抗剂。
Expert Opin Investig Drugs. 2016 Dec;25(12):1405-1412. doi: 10.1080/13543784.2016.1254616.
3
Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.Fischer 344大鼠：上皮性卵巢癌叶酸靶向治疗的临床前模型
Int J Gynecol Cancer. 2015 Sep;25(7):1194-200. doi: 10.1097/IGC.0000000000000497.
4
Exploiting the folate receptor α in oncology.在肿瘤学中利用叶酸受体α。
Nat Rev Clin Oncol. 2020 Jun;17(6):349-359. doi: 10.1038/s41571-020-0339-5. Epub 2020 Mar 9.
5
Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.评估一种新型叶酸靶向光敏剂对上皮性卵巢癌腹膜转移的特异性，以实现腹腔内光动力治疗。一项临床前研究。
Photodiagnosis Photodyn Ther. 2016 Mar;13:130-138. doi: 10.1016/j.pdpdt.2015.07.005. Epub 2015 Jul 19.
6
Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor alpha.通过叶酸受体 α 介导的主动靶向卵巢癌细胞的基因传递。
J Biomed Nanotechnol. 2013 May;9(5):833-44. doi: 10.1166/jbn.2013.1587.
7
Therapeutic strategies targeting folate receptor α for ovarian cancer.针对叶酸受体α的卵巢癌治疗策略。
Front Immunol. 2023 Aug 30;14:1254532. doi: 10.3389/fimmu.2023.1254532. eCollection 2023.
8
[FRα: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?].[FRα：卵巢腹膜转移预防性光动力治疗的靶点？]
Bull Cancer. 2014 Dec;101(12):1109-13. doi: 10.1684/bdc.2014.1977.
9
[Molecular targeted therapies for epithelial ovarian cancer].[上皮性卵巢癌的分子靶向治疗]
Nihon Rinsho. 2012 Jun;70 Suppl 4:622-7.
10
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.靶向叶酸受体：个性化癌症治疗的诊断和治疗方法。
Ann Oncol. 2015 Oct;26(10):2034-43. doi: 10.1093/annonc/mdv250. Epub 2015 Jun 10.

引用本文的文献

1
Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.抗体药物偶联物（ADCs）：当前及未来的生物制药
J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3.
2
Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?叶酸受体α——卵巢癌治疗的秘密武器？
Int J Mol Sci. 2024 Nov 6;25(22):11927. doi: 10.3390/ijms252211927.
3
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.FRα 高表达铂类敏感型卵巢癌患者中，采用 mirvetuximab soravtansine 联合贝伐珠单抗维持治疗对比贝伐珠单抗单药维持治疗的疗效。
Future Oncol. 2024;20(32):2423-2436. doi: 10.1080/14796694.2024.2372241. Epub 2024 Jul 31.
4
Effects of solid lipid nanocarrier containing methyl urolithin A by coating folate-bound chitosan and evaluation of its anti-cancer activity.载有甲基乌药堿的固体脂质纳米载体通过包覆叶酸结合壳聚糖的效果及其抗癌活性评价。
BMC Biotechnol. 2024 Apr 10;24(1):18. doi: 10.1186/s12896-024-00845-6.
5
Recent advances of novel targeted drug delivery systems based on natural medicine monomers against hepatocellular carcinoma.基于天然药物单体的新型靶向给药系统抗肝细胞癌的研究进展
Heliyon. 2024 Jan 18;10(2):e24667. doi: 10.1016/j.heliyon.2024.e24667. eCollection 2024 Jan 30.
6
The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer.紫杉醇和非瑟酮负载 PBM 纳米粒对卵巢癌细胞凋亡及耐药基因 ABCG2 逆转的影响。
J Ovarian Res. 2023 Nov 21;16(1):220. doi: 10.1186/s13048-023-01308-w.
7
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023.妇科恶性肿瘤的最新进展：聚焦2023年美国临床肿瘤学会（ASCO）年会
Oncol Ther. 2023 Dec;11(4):397-409. doi: 10.1007/s40487-023-00244-5. Epub 2023 Sep 15.
8
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.预测抗体药物偶联物的反应：聚焦于抗原的靶向性。
Oncologist. 2023 Nov 2;28(11):944-960. doi: 10.1093/oncolo/oyad246.
9
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.Mirvetuximab Soravtansine用于铂耐药卵巢癌的治疗
Clin Med Insights Oncol. 2023 Jul 25;17:11795549231187264. doi: 10.1177/11795549231187264. eCollection 2023.
10
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.FDA 批准概要：Mirvetuximab Soravtansine-Gynx 用于 FRα 阳性、铂耐药性卵巢癌。
Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991.

本文引用的文献

1
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.米拉妥昔单抗soravtansine 治疗铂耐药卵巢癌的研究综述。
Future Oncol. 2018 Jan;14(2):123-136. doi: 10.2217/fon-2017-0379. Epub 2017 Nov 3.
2
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.复发性上皮性卵巢癌患者存档肿瘤和活检样本中叶酸受体α（FRα）表达的特征分析：靶向FRα的抗体药物偶联物mirvetuximab soravtansine的I期扩展研究。
Gynecol Oncol. 2017 Nov;147(2):402-407. doi: 10.1016/j.ygyno.2017.08.015. Epub 2017 Aug 24.
3
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.Mirvetuximab Soravtansine（IMGN853），一种靶向叶酸受体α的抗体药物偶联物，在铂耐药卵巢癌、输卵管癌或原发性腹膜癌中的安全性和活性：一项I期扩展研究。
J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.
4
Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.铂类耐药/难治性卵巢癌和原发性宫颈腺癌中叶酸受体α的表达
Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):567-572. doi: 10.1097/PAI.0000000000000476.
5
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.P-糖蛋白/多药耐药蛋白的高表达导致对维替泊芬耐药。
Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2.
6
Profile of farletuzumab and its potential in the treatment of solid tumors.法乐妥珠单抗概况及其在实体瘤治疗中的潜力。
Onco Targets Ther. 2016 Mar 7;9:1181-8. doi: 10.2147/OTT.S98242. eCollection 2016.
7
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.一项随机、双盲、安慰剂对照、III 期研究，旨在评估每周 farletuzumab 联合卡铂和紫杉烷治疗在铂类敏感复发的卵巢癌患者中的疗效和安全性。
J Clin Oncol. 2016 Jul 1;34(19):2271-8. doi: 10.1200/JCO.2015.63.2596. Epub 2016 Mar 21.
8
Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia.叶酸受体α在子宫内膜样腺癌和子宫内膜增生中的表达及意义
Int J Clin Exp Pathol. 2015 May 1;8(5):5633-41. eCollection 2015.
9
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.IMGN853，一种叶酸受体-α（FRα）靶向抗体药物偶联物，对 FRα 表达的肿瘤表现出强大的靶向抗肿瘤活性。
Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.
10
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.叶酸受体在卵巢癌治疗中的作用：证据、机制及临床意义。
Cancer Metastasis Rev. 2015 Mar;34(1):41-52. doi: 10.1007/s10555-014-9539-8.

靶向卵巢癌中的叶酸受体是否已成熟？

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

机构信息

O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA

O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.

出版信息

Oncologist. 2019 Apr;24(4):425-429. doi: 10.1634/theoncologist.2018-0459. Epub 2019 Jan 11.

DOI:10.1634/theoncologist.2018-0459
PMID:30635448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6459241/
Abstract

Prognosis for women with epithelial ovarian cancer remains poor. One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα). This commentary discusses the characteristics that contribute to its attractiveness as a candidate for therapeutic intervention.

摘要

上皮性卵巢癌患者的预后仍然较差。上皮性卵巢癌的一个新的分子靶点是叶酸受体α（FRα）。本评论讨论了其作为治疗干预候选物的吸引力的特征。